Literature DB >> 28370253

Association between disease activity and quality of life in ulcerative colitis: Results from the CRONICA-UC study.

Julián Panés1, Eugeni Domènech2, Marian Aguas Peris3, Pilar Nos3, Sabino Riestra4, Berta Juliá de Páramo5, Luis Cea-Calvo5, Cristina Romero5, Ignacio Marín-Jiménez6.   

Abstract

BACKGROUND AND AIM: In ulcerative colitis (UC), the main goals of treatment are to control disease activity and normalize health-related quality of life (HRQoL). In this study, we explored the relationship between disease activity (measured using the Simple Clinical Colitis Activity Index [SCCAI]) and patient HRQoL (measured using the EuroQoL [EQ]-5D-5L).
METHODS: A total of 199 patients with UC were followed for 6 months. At months 3 and 6, patients completed an online SCCAI. Within 2 days of completing the SCCAI, patients completed an at-clinic EQ-5D-5L questionnaire and the treating gastroenterologist completed the SCCAI.
RESULTS: A consistent and approximately linear relationship was identified between patient HRQoL and patient-completed and physician-completed SCCAIs. A lower SCCAI score corresponded to a higher EQ-5D-5L index value. Correlation between EQ-5D-5L index values and patient-completed online SCCAIs was moderate (ρ -0.49; P < 0.001) and similar to that between EQ-5D-5L index values and physician-completed SCCAIs (ρ -0.53; P < 0.001). A decrease in the EQ-5D-5L index was already observed at an SCCAI score of 2, commonly regarded as remission. A 1-point increase in the patient SCCAI corresponded to an average change of -0.027 (standard deviation, -0.032 to -0.022) in the EQ-5D-5L index, whereas a 1-point increase in the physician SCCAI corresponded to an average change of -0.030 (standard deviation, -0.036 to -0.025).
CONCLUSIONS: Health-related quality of life measured using the EQ-5D-5L questionnaire is proportionally related to disease activity in patients with UC. In line with the treat-to-target objective in UC, complete control of all symptoms is required to achieve optimal improvement in patient HRQoL.
© 2017 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  disease activity; health-related quality of life; questionnaire; symptoms; ulcerative colitis

Mesh:

Year:  2017        PMID: 28370253     DOI: 10.1111/jgh.13795

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  6 in total

1.  Cost-effectiveness analysis of infliximab, adalimumab, golimumab, vedolizumab and tofacitinib for moderate to severe ulcerative colitis in Spain.

Authors:  Cristina Trigo-Vicente; Vicente Gimeno-Ballester; Alejandro López-Del Val
Journal:  Eur J Hosp Pharm       Date:  2019-05-07

2.  Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus.

Authors:  Marco Daperno; Alessandro Armuzzi; Silvio Danese; Walter Fries; Giuseppina Liguori; Ambrogio Orlando; Claudio Papi; Mariabeatrice Principi; Fernando Rizzello; Angelo Viscido; Paolo Gionchetti
Journal:  Gastroenterol Res Pract       Date:  2019-09-02       Impact factor: 2.260

3.  Golimumab improves work productivity in patients suffering from moderate to severe ulcerative colitis: results of a prospective study over 24 months.

Authors:  Niels Teich; Harald Grümmer; Eric Jörgensen; Thomas Liceni; Frank Holtkamp-Endemann; Tim Fischer; Susanne Hohenberger
Journal:  BMC Gastroenterol       Date:  2021-04-12       Impact factor: 3.067

4.  Impact of adalimumab on disease burden in moderate-to-severe ulcerative colitis patients: The one-year, real-world UCanADA study.

Authors:  Talat Bessissow; Geoffrey C Nguyen; Osman Tarabain; Laurent Peyrin-Biroulet; Nathalie Foucault; Kevin McHugh; Joannie Ruel
Journal:  World J Gastroenterol       Date:  2022-09-14       Impact factor: 5.374

5.  The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe.

Authors:  Alessandro Armuzzi; Miriam Tarallo; James Lucas; Daniel Bluff; Benjamin Hoskin; Danielle Bargo; Joseph C Cappelleri; Leonardo Salese; Marco daCosta DiBonaventura
Journal:  BMC Gastroenterol       Date:  2020-01-21       Impact factor: 3.067

6.  Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis.

Authors:  Subrata Ghosh; Yuri Sanchez Gonzalez; Wen Zhou; Ryan Clark; Wangang Xie; Edouard Louis; Edward V Loftus; Julian Panes; Silvio Danese
Journal:  J Crohns Colitis       Date:  2021-12-18       Impact factor: 9.071

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.